GRI Bio to Participate in the Virtual Investor Closing Bell Series

Live webcast on Wednesday, May 28^th at 4:00 PM ET

LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET.

Read more at globenewswire.com